Genprex
GNPXGenprex is a clinical-stage biotechnology company developing gene-based therapies for large patient populations with significant unmet medical needs in oncology and diabetes.
Earnings
Next report
Dec 2, 2026 (in 2 months)Competitors
By market cap
By revenue growth
Profile
Genprex is a clinical-stage biotechnology company developing gene-based therapies for large patient populations with significant unmet medical needs in oncology and diabetes. The company's core value proposition centers on its proprietary ONCOPREX Delivery System, a non-viral, systemic platform that delivers tumor suppressor genes to cancer cells, and an AAV-based gene therapy approach for diabetes. Their lead programs aim to enhance the efficacy of existing targeted therapies and immunotherapies through multimodal mechanisms of action.
Genprex is a pioneer in systemic, non-viral gene therapy for cancer, holding exclusive worldwide licenses for key tumor suppressor genes and novel diabetes gene therapy technologies.
FAQ
- What is Genprex's market cap?
- Genprex (GNPX) has a market capitalization of $2.8M and trades on NASDAQ.
- Who are Genprex's competitors?
- Genprex's key competitors include Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, and others. These companies compete in similar markets and product categories.
- Who does Genprex partner with?
- Genprex's notable partners include The University of Texas MD Anderson Cancer Center, University of Pittsburgh, AstraZeneca, and others.
- What subsidiaries does Genprex have?
- Genprex's subsidiaries include Convergen Biotech, Inc..
- Where is Genprex headquartered?
- Genprex is headquartered in United States of America and employs approximately 25 people. It has been publicly traded since 2018.